Bambusa Therapeutics Presented Positive Results from the Phase 1 Multiple Ascending Dose Trial of BBT001 at the 2026 American Academy of Dermatology (AAD) Annual Meeting
– Bambusa’s lead product candidate, BBT001 is a next-generation long-acting bispecific antibody…